胆固醇水平不能预测阿尔茨海默症风险
http://www.100md.com
2001年5月14日
NEW YORK May 11 (Reuters Health) - Lifetime cholesterol levels cannot predict a person's risk of developing Alzheimer's disease (news - web sites), according to results of a study presented Thursday at the American Geriatrics Society meeting in Chicago, Illinois.
``This study clearly shows that cholesterol is not related to the risk of Alzheimer's disease,''Dr. Zaldy S. Tan of Harvard Medical School (news - web sites) in Boston, Massachusetts, told Reuters Health.
These findings have implications for the theory that cholesterol-lowering drugs known as statins may reduce the risk of developing Alzheimer's disease, he said. ``Statin drugs probably have another mechanism of action other than cholesterol-lowering to account for the observed effect of reducing the risk of Alzheimer's disease,'' he noted.
Tan and colleagues analyzed the impact of lifetime cholesterol levels on the risk of developing Alzheimer's disease in 5,209 individuals participating in the Framingham study, a long-term, community-based health study, which is taking place in Framingham, Massachusetts..
Their study sample consisted of more than 1,000 people, average age 76, who were alive and stroke- and dementia-free as of 1991, had apolipoprotein E (APOE) gene information, and had had their cholesterol tested between 1987 and 1988. Of these, about 600 were women. One version of the APOE gene has been found to increase a person's risk of developing Alzheimer's.
Between 1992 and 2000, 76 of the people in the study had developed Alzheimer's disease.
After adjusting for age, sex, APOE, heart disease and diabetes, as well as smoking and body mass index (a height-weight ratio used to gauge whether a person is obese), Tan and colleagues found no significant association between cholesterol levels and the risk of developing Alzheimer's disease.
Tan believes these findings indicate that ``people who have normal cholesterol levels may be good candidates for ongoing trials looking at the use of statins for the prevention of Alzheimer's disease.'', 百拇医药
``This study clearly shows that cholesterol is not related to the risk of Alzheimer's disease,''Dr. Zaldy S. Tan of Harvard Medical School (news - web sites) in Boston, Massachusetts, told Reuters Health.
These findings have implications for the theory that cholesterol-lowering drugs known as statins may reduce the risk of developing Alzheimer's disease, he said. ``Statin drugs probably have another mechanism of action other than cholesterol-lowering to account for the observed effect of reducing the risk of Alzheimer's disease,'' he noted.
Tan and colleagues analyzed the impact of lifetime cholesterol levels on the risk of developing Alzheimer's disease in 5,209 individuals participating in the Framingham study, a long-term, community-based health study, which is taking place in Framingham, Massachusetts..
Their study sample consisted of more than 1,000 people, average age 76, who were alive and stroke- and dementia-free as of 1991, had apolipoprotein E (APOE) gene information, and had had their cholesterol tested between 1987 and 1988. Of these, about 600 were women. One version of the APOE gene has been found to increase a person's risk of developing Alzheimer's.
Between 1992 and 2000, 76 of the people in the study had developed Alzheimer's disease.
After adjusting for age, sex, APOE, heart disease and diabetes, as well as smoking and body mass index (a height-weight ratio used to gauge whether a person is obese), Tan and colleagues found no significant association between cholesterol levels and the risk of developing Alzheimer's disease.
Tan believes these findings indicate that ``people who have normal cholesterol levels may be good candidates for ongoing trials looking at the use of statins for the prevention of Alzheimer's disease.'', 百拇医药